Harvard Bioscience (HBIO) Shares Outstanding (Weighted Average) (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 1.43% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 1.43% YoY) and the FY2025 annual result came in at $44.4 million, up 1.96% from the prior year.
• Shares Outstanding (Weighted Average) declined to $4.5 million in Q1 2026 per HBIO's latest filing, from $44.4 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $44.4 million in Q4 2025 and bottomed at $4.4 million in Q1 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $42.4 million (2023), against an average of $38.2 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 102763.04%; it then plunged 89.84% in 2025.
• Tracing HBIO's Shares Outstanding (Weighted Average) over 5 years: stood at $41.4 million in 2022, then advanced by 2.43% to $42.4 million in 2023, then advanced by 2.64% to $43.5 million in 2024, then increased by 1.96% to $44.4 million in 2025, then plunged by 89.92% to $4.5 million in 2026.
• Per Business Quant, the three latest HBIO Shares Outstanding (Weighted Average) figures stand at $4.5 million (Q1 2026), $44.4 million (Q4 2025), and $44.3 million (Q3 2025).

Peer Comparison